Hypertrophic cardiomyopathy in elderly: causes, diagnostic and treatment approaches
- Authors: Chumakova O.S.1
-
Affiliations:
- Central State Medical Academy of the President of the Russian Federation
- Issue: Vol 92, No 9 (2020)
- Pages: 63-69
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/46857
- DOI: https://doi.org/10.26442/00403660.2020.09.000558
- ID: 46857
Cite item
Full Text
Abstract
Hypertrophic cardiomyopathy is the most common inherited heart disorder with high clinical heterogeneity. Every fifth patient is older than 60 years at first diagnosis. This review discusses the possible causes for the late onset of hypertrophic cardiomyopathy, the diagnostic and treatment approaches in the elderly.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
O. S. Chumakova
Central State Medical Academy of the President of the Russian Federation
Author for correspondence.
Email: chumakovaolga@bk.ru
ORCID iD: 0000-0003-2373-1183
к.м.н., доц. каф. терапии, кардиологии и функциональной диагностики с курсом нефрологии
Russian Federation, MoscowReferences
- Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi: 10.1016/j.jacc.2015.01.019
- Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121(7):749-70. doi: 10.1161/CIRCRESAHA.117.311059
- Maron BJ, Harris KM, Spirito P, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-25. doi: 10.1161/CIRCULATIONAHA.105.583500
- Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973;2(7844):1462-7. doi: 10.1016/s0140-6736(73)92730-x
- Charron P, Elliott PM, Gimeno JR, et al.; EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39(20):1784-93. doi: 10.1093/eurheartj/ehx819
- Maron BJ, Rowin EJ, Casey SA, et al. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016;117(3):434-5. doi: 10.1016/j.amjcard.2015.11.013
- Maron BJ, Casey SA, Haas TS, et al. Hypertrophic Cardiomyopathy With Longevity to 90 Years or Older. Am J Cardiol. 2012;109(9):1341-7. doi: 10.1016/j.amjcard.2011
- Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-98. doi: 10.1161/CIRCULATIONAHA.117.033200
- Maron BJ, Casey SA, Maron MS. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. Shaped by 50 Years of Clinical Research and Practice. JAMA Cardiol. 2016;1(1):98-105. doi: 10.1001/jamacardio.2015.0354
- Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2019; p. E1-E8. doi: 10.1001/jamacardio.2019.4534
- Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al. A Molecular Basis for Familial Hypertrophic Cardiomyopathy: A beta Cardiac Myosin Heavy Chain Gene Missense Mutation. Cell. 1990;62:999-1006. doi: 10.1016/0092-8674(90)90274-i
- Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(15):1978-86. doi: 10.1016/j.jacc.2019.01.061
- Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2):e001620. doi: 10.1161/CIRCGENETICS.116.001620
- Anan R, Niimura H, Takenaka T, et al. Mutations in the genes for sarcomeric proteins in Japanese patients with onset sporadic hypertrophic cardiomyopathy after age 40 years. Am J Cardiol. 2007;99(12):1750-4. doi: 10.1016/j.amjcard.2007.01.066
- Hirota T, Kitaoka H, Kubo T, et al. Morphologic characteristics of hypertrophic cardiomyopathy of the elderly with cardiac myosin-binding protein C gene mutations. Circ J. 2006;70(7):875-9. doi: 10.1253/circj.70.875
- Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89(6):727-37. doi: 10.1016/j.mayocp.2014.01.025
- Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-8. doi: 10.1038/gim.2014.205
- Bagnall RD, Ingles J, Dinger ME, et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2018;72(4):419-29. doi: 10.1016/j.jacc.2018.04.078
- Van Driest SL AM, Ommen SR, Shakur R, et al. Prevalence and severity of «benign» mutations in the beta-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002;106(24):3085-90. doi: 10.1161/01.cir.0000042675.59901.14
- Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, et al. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart. 2010;96(24):1980-4. doi: 10.1136/hrt.2010.200402
- Jansweijer JA, van Spaendonck-Zwarts KY, Tanck MWT, et al. Heritability in genetic heart disease: the role of genetic background. Open Heart. 2019;6(1):e000929. doi: 10.1136/openhrt-2018-000929
- Cerrone M, Remme CA, Tadros R, et al. Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders. Circulation. 2019;140(7):595-610. doi: 10.1161/CIRCULATIONAHA.118.035954
- Li L, Bainbridge MN, Tan Y, et al. A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder. Circ Res. 2017;120(7):1084-90. doi: 10.1161/CIRCRESAHA.116.310559
- Burns C, Bagnall RD, Lam L, et al. Multiple Gene Variants in Hypertrophic Cardiomyopathy in the Era of Next-Generation Sequencing. Circ Cardiovasc Genet. 2017;10(4):e001666. doi: 10.1161/CIRCGENETICS.116.001666
- Mouton JM, van der Merwe L, Goosen A, et al. MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients. Hum Genet. 2016;135(5):477-83. doi: 10.1007/s00439-016-1649-7
- Wooten EC, Hebl VB, Wolf MJ, et al. Formin Homology 2 Domain Containing 3 (FHOD3) Variants Associated with Hypertrophic Cardiomyopathy. Circ Cardiovasc Genet. 2013;6(1):10-8. doi: 10.1161/CIRCGENETICS.112.965277
- Perkins MJ Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J. 2005;26:2457-62. doi: 10.1093/eurheartj/ehi438
- Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87:270-5. doi: 10.1136/heart.87.3.270
- Kolder IC, Michels M, Christiaans I, et al. The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum Genet. 2012;20(10):1071-7. doi: 10.1038/ejhg.2012.48
- Axelsson A, Iversen K, Vejlstrup N, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-31. doi: 10.1016/S2213-8587(14)70241-4
- Maron MS, Chan RH, Kapur NK, et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018;131(7):837-41. doi: 10.1016/j.amjmed.2018.02.025
- Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81(4):459-67. doi: 10.4065/81.4.459
- Kubo T, Kitaoka H, Okawa M, et al. Hypertrophic cardiomyopathy in the elderly. Geriatr Gerontol Int. 2010;10(1):9-16. doi: 10.1111/j.1447-0594.2009.00572.x
- Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation. 1989;79(3):580-9. doi: 10.1161/01.cir.79.3.580
- Canepa M, Malti O, David M, et al. Prevalence, Clinical Correlates and Functional Impact of Subaortic Ventricular Septal Bulge (From the Baltimore Longitudinal Study of Aging). Am J Cardiol. 2014;114(5):796-802. doi: 10.1016/j.amjcard.2014.05.068
- Ranasinghe I, Ayoub C, Cheruvu C, et al. Isolated hypertrophy of the basal ventricular septum: characteristics of patients with and without outflow tract obstruction. Int J Cardiol. 2014;173(3):487-93. doi: 10.1016/j.ijcard.2014.03.078
- Turer AT, Samad Z, Valente AM, et al. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(2):131-9. doi: 10.1093/ejechocard/jeq163
- Bos JM, Will M, Ommen S, et al. Yield of genetic testing among patients with hypertrophic cardiomyopathy diagnosed after 65 years of age. JACC. 2013;61(10):E1305. doi: 10.1016/S0735-1097(13)61305-4
- Hata Y, Ichimata S, Yamaguchi Y, et al. Clinicopathological and Genetic Profiles of Cases with Myocyte Disarray - Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. J Clin Med. 2019;8(4):463. doi: 10.3390/jcm8040463
- Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature and typing. Cardiovascular Pathology. 2015;24(6):343-50. doi: 10.1016/j.carpath.2015.07.008
- Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2019:S0167-5273(19)30935-0. doi: 10.1016/j.ijcard.2019.07.051
- González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. doi: 10.1093/eurheartj/ehv338
- Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31-40. doi: 10.1086/504601
- Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi: 10.1016/j.jacc.2007.06.062
- Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407-11. doi: 10.1161/01.cir.0000012626.81324.38
- Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-18. doi: 10.1002/ejhf.541
- Leong KMW, Chow JJ, Ng FS, et al. Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;121(3):349-55. doi: 10.1016/j.amjcard.2017.10.027
- Ушкалова Е.А. Зырянов С.К., Затолочина К.Э. и др. Применение антиаритмических средств у пожилых пациентов. Препараты I и II класса по классификации Вогана-Вильямса. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):471-8 [Ushkalova EA, Zyryanov SK, Zatolochina KE, et al. Antiarrhythmic drugs use in elderly patients. Vaughan Williams class I and II drugs. Rational Pharmacotherapy in Cardiology. 2016;12(4):471-8 (In Russ.)]. doi: 10.20996/1819-6446-2016-12-4-471-478
- Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783-831. doi: 10.1161/CIR.0b013e318223e2bd
- Liebregts M, Steggerda RC, Vriesendorp PA, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2016;9(5):463-9. doi: 10.1016/j.jcin.2015.11.036
- Kimmelstiel C, Zisa DC, Kuttab JS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019;12(7):e007673. doi: 10.1161/CIRCINTERVENTIONS.118.007673
- Maron BJ, Rowin EJ, Casey SA, et al. Risk Strati cation and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age. Circulation. 2013;127(5):585-93. doi: 10.1161/CIRCULATIONAHA.112.136085
- Guttmann OP, Rahman MS, O’Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465-72. doi: 10.1136/heartjnl-2013-304276
- Guttmann OP, Pavlou M, O’Mahony C, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017;103(9):672-8. doi: 10.1136/heartjnl-2016-309672
- Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017;136(25):2420-36. doi: 10.1161/CIRCULATIONAHA.117.029267
- Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24(2):189-97. doi: 10.1007/s10741-018-9752-6